Samil Pharmaceutical삼일제약
000520 · KOSPI · ₩000520 · 삼일제약
₩7,780▲ ₩140 (1.83%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩210B | ₩220B | ₩196B | ₩180B | ₩134B |
| Cost of sales | ₩133B | ₩139B | ₩122B | ₩112B | ₩85B |
| Gross profit | ₩77B | ₩81B | ₩74B | ₩67B | ₩49B |
| Operating income | −₩22B | ₩113M | ₩6.5B | ₩4B | ₩400M |
| Net income | −₩35B | −₩5.6B | ₩1.7B | −₩28M | −₩5.3B |
| Net income to shareholders | −₩35B | −₩5.6B | ₩1.7B | −₩28M | −₩5.3B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩372B | ₩395B | ₩371B | ₩357B | ₩226B |
| Current assets | ₩82B | ₩91B | ₩81B | ₩75B | ₩77B |
| Cash and equivalents | ₩6.4B | ₩5.1B | ₩906M | ₩1.9B | ₩4B |
| Total liabilities | ₩238B | ₩219B | ₩243B | ₩231B | ₩161B |
| Current liabilities | ₩185B | ₩107B | ₩169B | ₩133B | ₩122B |
| Borrowings | ₩162B | ₩148B | ₩174B | ₩157B | ₩124B |
| Total equity | ₩133B | ₩176B | ₩128B | ₩126B | ₩66B |
| Shareholders' equity | ₩133B | ₩176B | ₩128B | ₩126B | ₩66B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩568M | ₩2.6B | ₩12B | ₩4.2B | ₩1.4B |
| Capital spending | ₩7.5B | ₩5.4B | ₩24B | ₩48B | ₩33B |
| Free cash flow | −₩6.9B | −₩2.8B | −₩12B | −₩44B | −₩31B |
| Dividends paid | ₩0 | ₩0 | ₩0 | ₩1B | ₩939M |
Consolidated where available. Amounts in won.
Also known as: Samil Pharmaceutical / 삼일제약 / 000520 / KRX:000520
Source: KRX statistical information